

Q2 2025 Results

2025.08.08

DISCLAIMER



This presentation reflects the direction Seegene may take with regard to the products or services described herein, all of which is subject to change without notice. Any statement in this presentation about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. This presentation is not a commitment to you in any way and you should not rely on any content herein in making any decision.

Seegene is not committing to develop or deliver any specified enhancement, upgrade, product, service or functionality, even if such is described herein. Many factors can affect Seegene's product development plans and the nature, content and timing of future product releases, all of which remain in the sole discretion of Seegene.

This presentation, in whole or in part, may not be incorporated into any agreement. The information set forth in this presentation does not purport to be complete or without error, and no obligation to update or otherwise revise such information is being assumed. Seegene expressly disclaims any liability with respect to this presentation.

01 **Key Highlights**

- Q2 Earnings
- Business update

02 **Financial Summary**

- Q2 IS/BS/CF
- Quarterly sales breakdown

03 **Business Update**

- CURECA™
- STAgora™

04 **Appendix**

- Product sales breakdown
- Sales by region
- Company ratios
- Company & stock information

01

Key Highlights

Q2 Earnings

Business update

Q2 Earnings

Non-Covid syndromic growth continues,
Total sales increased YoY +13.9%

- ✓ Sales W114bn (QoQ -1.7%, YoY +13.9%)
- ✓ RV -15.6% , PB -15.9% // GI +30.9%, HPV +21.4% YoY
Non-Covid sales growth continues (YoY +7.1%)
- ✓ Respiratory product sales declined due to the subsiding of regional outbreaks and the onset of the off-season
- ✓ GI and HPV product sales continued to show solid growth

Recorded an operating profit of W 3.1 billion

- ✓ OP W 3.1bn / NP - W 0.1bn
- ✓ COGS increased due to a higher proportion of merchandise sales compared to Q1
- ✓ Slight increase in SG&A and R&D expenses
- ✓ Profit decline vs. 1Q also due to base effect from lower exchange rates and one-off reversals in Q1

Business Update

CURECA™ and STAgora™ unveiled at the ADLM 2025 ,
offering opportunity to experience a new diagnostic paradigm

CURECA™: An unmanned PCR automation system

- ✓ Full Automation: Covers the entire PCR testing workflow — from sample loading and storage, preprocessing, nucleic acid extraction, amplification, to result analysis — without manual intervention.
- ✓ Modular Design: Flexible combination and arrangement allow application in laboratories of all environments.
- ✓ Preprocessing Innovation: The CURECA™ Prep module effectively solves the biggest challenge in full automation — manual sample preprocessing.
- ✓ Versatility: Applicable to other diagnostic fields such as clinical chemistry and immunoassay, with the potential to significantly advance the overall automation level of the diagnostic industry.

STAgora™: Real-time Diagnostic Data Sharing and Analysis Platform

- ✓ Clinical Decision Support: Collects and analyzes PCR test data in real time, providing statistical insights to assist healthcare professionals in clinical decision-making.
- ✓ Global Data Integration: Delivers real-time infectious disease diagnostic data at the hospital, national, and global levels, enabling critical insights for diagnosis and treatment.

02

Financial Summary

Q2 IS/BS/CF

Quarterly sales breakdown

(Unit: W Bn)	Q2.25	Q1.25	QoQ	Q2.24	YoY
Revenue	114.1	116.0	-1.7%	100.1	13.9%
Cost of Good Sold	44.8	37.3		36.6	
(%)	39%	32%		37%	
Gross Profit	69.2	78.7	-12.0%	63.6	8.9%
SG&A Exp.	48.5	47.9		46.0	
(%)	43%	41%		46%	
R&D Exp.	17.6	16.0		18.7	
(%)	15%	14%		19%	
Operating Profit	3.1	14.8	-78.8%	-1.1 Trn Blk	
(%)	3%	13%		-1%	
Non-Operating Gain/Loss	-3.9	8.7	Trn Red	30.0	Trn Red
Financial Gains (Loss)	-5.2	8.7		8.3	
Income/(Loss) from Affiliates	1.0	0.5		3.3	
Other Non-Operatring Inc. (Exp.)	0.2	-0.5		18.3	
Pretax Income	-0.8	23.5	Trn Red	28.8	Trn Red
(%) (%)	-1%	20%		29%	
Income Tax Exp.	-0.7	-5.4		4.8	
Net Earnings	-0.1	28.9 Trn Red		24.1 Trn Red	
(%)	-0.1%	25%		24%	

Sales W114 bn (QoQ -0.7%, YoY +13.9%)

- Non-COVID reagent sales grew % YoY
- Respiratory product sales declined due to the subsiding of regional outbreaks and the onset of the off-season
- RV -15.6%, PB -15.9% // GI +30.9%, HPV +21.4% YoY
- GI and HPV product sales continued to show solid growth

Operating profit W3.1bn / Net profit -W0.1bn

- COGS increased due to a higher proportion of merchandise sales compared to Q1
- Profit decline vs. 1Q also due to base effect from lower exchange rates and one-off reversals in Q1

Financial Summary | Q2 BS/CF



(Unit: W Bn)	Q2.25	Q2.24
Asset	1212.6	1267.6
· Cash and equivalents	388.6	429.3
· Financial assets measured at fair value	155.7	100.7
· Account/other receivables	98.8	96.3
· Inventory	95.9	123.5
· Accounts receivable long-term	30.3	32.4
· Gross PP&E	223.3	235.0
· Other Assets	220.1	250.5
Liabilities	219.4	224.5
· Account/other payables	35.7	37.4
· Short-term borrowings	35.0	35.0
· Curr. Port. Of LT Debt	40.8	40.8
· Income taxes payable	2.5	1.0
· Long-term debt	1.0	1.1
· Other Liabilities	104.4	109.1
Equity	993.1	1043.2
· Common stock	26.1	26.1
· Additional paid in capital	-109.7	-111.9
· Retained earnings	1073.8	1126.1
· Minority interest	2.9	2.9


(Unit: W Bn)	Q2.25	2024
Beginning Cash Balance	259.7	190.3
Cashflow From Operations	66.3	85.4
· Net Income	28.9	-20.3
· Change in Net Capital Mngt	-4.9	-14.0
· Income Tax Paid	10.2	-3.1
· Others	32.1	122.7
Cashflow From Investments	-27.5	34.7
· Sale (Purcahse) of PP&E	-18.5	-3.6
· Sale (Purchase) of Intangible Assets	-2.2	27.3
· Invest in short term investments	-83.4	-2.3
· Others	76.6	13.3
Cashflow From Finance	-32.1	-63.7
· Dividends Paid	0.0	-2.4
· Lease Redemption	-10.7	-36.9
· Change in leasehold deposit	0.0	0.0
· Treasury stock purchase	-1.7	-2.4
· Others	-19.7	-3.3
FX adujstment	2.4	13.0
Net Change in Cash	9.1	69.4
Ending Cash Balance	268.8	259.7

*Cash and equivalents include short term investment in financial instruments

*CF is based on an annual basis

*Based on preliminary results Q2 2025

Higher Non-COVID reagent sales growth vs. *market outlook
(global molecular diagnostics growth 4.0% CAGR 2024-2030)



** Source: Grand View Research: Molecular Diagnostics Market Estimates & Trend Analysis (2024)

03



Business Update

CURECA™

STAgora™

CURECA™ & STAgora™ unveiled at ADLM (07.28~31)

- CURECA™ is a fully automated system designed to handle the entire PCR testing process — from sample storage and loading, preprocessing, nucleic acid extraction, amplification, to result analysis — without any manual intervention
- The CURECA™ Prep module effectively addresses the long-standing challenge in laboratories of manual sample preprocessing, significantly reducing workload and improving efficiency



* ACE: A primary sample storage device that is Attachable, Customizable, and Expandable
ACE System : Seegene's proprietary solution leveraging the ACE storage device to significantly expand processing capacity



CURECA™ & STAgora™ unveiled at ADLM (07.28~31)

- Our statistical platform that collects and analyzes PCR test data in real time to support clinical decision-making. Based on data uploaded from individual hospitals, it analyzes regional infection trends, hospital-specific positivity rates, and co-infection patterns, offering more than 40 clinical decision-support statistical tools.
- Enables healthcare professionals to compare and analyze each patient's infection profile against local infection rates, facilitating the development of more precise, data-driven treatment strategies.



Harnessing Integrated Global Data

- Global Surveillance Data: Provides worldwide infectious disease surveillance data
- Granular Trend Analysis: Enables trend monitoring down to continent, country, and city levels; available when users agree to share global data
- Customized Pathogen Tracking: Allows users to set and track specific pathogens of interest




Empowering clinicians with accurate diagnostic support

- Treatment Decision Assistance: Supports clinicians in patient care and prescription decisions
- Comprehensive PCR Results Management: Provides patient-specific consolidated PCR test results with options for documentation and download
- Personalized Analysis Reports: Delivers individual comprehensive analysis reports, incorporating global statistical data when applicable



Customized analysis for syndromic testing

- Optimized for Seegene's High-Multiplex Syndromic Panels: Supports comprehensive analysis of panels such as RV (27 targets), RTI (28 targets), GI (35 targets), and HPV (14 or 28 targets)
- Comprehensive & AI-Driven Data Analysis: Performs integrated result analysis and AI-based interpretation of complex syndromic data
- Extensive Visualization Capabilities: Generates over 40 types of analytical graphs, including single-pathogen, syndromic, co-infection, and positivity rate trends



Leveraging existing laboratory data through seamless integration

- Migration of existing laboratory data: Integrates and consolidates data already held by the laboratory
- Lab-to-Lab Data Connectivity: Enables inter-laboratory data sharing and unified management



Customized Comprehensive Reports & Dashboards for Clients

- Configure and display a variety of charts through customizable widgets
- Tailor functions to match each laboratory's IT environment.
- Operate unified data systems across connected laboratories

04

Appendix

Product sales breakdown

Sales by region breakdown

Company ratios


Company & stock information

Appendix | Product sales breakdown



2025 Q2 Non-COVID reagent sales grew 7.1% YoY
 RV(YoY -15.6%), PB (YoY -15.9%), GI (YoY 30.9%), HPV (YoY 21.4%).

(Unit: W Bn)	Q2.22	Q3.22	Q4.22	Q1.23	Q2.23	Q3.23	Q4.23	Q1.24	Q2.24	Q3.24	Q4.24	Q1.25	Q2.25
Reagent	105.6	115.5	108.2	67.7	66.7	75.1	78.5	72.7	82.2	90.4	89.7	94.3	87.5
- Diagnostic Products	97.4	106.7	99.5	59.6	60.2	67.1	69.3	63.8	74.4	80.8	79.5	83.2	78.0
COVID	59.3	64.2	47.3	13.3	10.3	9.2	8	6.2	3.9	3.9	3.4	4.0	2.5
Non-COVID	38.1	42.5	52.2	46.3	49.9	57.9	61.3	57.6	70.5	76.9	76.1	79.2	75.5
- Extraction	8.2	8.8	8.7	8.1	6.5	7.9	9.1	8.9	7.8	9.6	10.2	11.1	9.5
Equipment etc.	22.9	35.3	14.5	22.4	18.2	16.8	22	17.3	17.9	18.4	25.6	21.7	26.6
Total	128.4	150.8	122.7	90.1	84.9	91.9	100.5	89.9	100.1	108.8	115.3	116.0	114.1
Non-COVID	39.7%	21.9%	39.8%	47.4%	31.0%	36.0%	17.4%	24.4%	41.3%	32.8%	24.1%	37.5%	7.1%




Appendix | Sales by region breakdown



(Unit: W bn)	Q1.25	Q2.24	Q2.25
EU	74.5	54.9	69.1
N.America	5.1	6.1	5.3
CSA	8.5	9.8	11.4
Asia	17.2	20.6	19.2
Domestic	10.7	8.8	9.1
Total	116.0	100.1	114.1


* Asia: includes middle east, Africa, Oceania



Appendix | Company & stock information



● HQ ● Sales subsidiary ● Branch



* 2024, End of Dec

Agencies in **85** countries

EUROPE

Austria	Germany	Poland
Belarus	Georgia	Romania
Belgium	Greece	Serbia
Bulgaria	Hungary	Slovenia
Croatia	Ireland	Spain
Czech Republic	Italy	Sweden
Denmark	Latvia	Switzerland
Estonia	Lithuania	Ukraine
Finland	Macedonia	United Kingdom
France		

ASIA

Bangladesh	Kazakhstan	Singapore
Brunei	Lebanon	Sri Lanka
China	Malaysia	Taiwan
Hong Kong	Mongolia	Thailand
India	Nepal	Turkey
Indonesia	Philippines	United Arab Emirates
Israel	Qatar	Vietnam
Japan	Republic of Korea	
Jordan	Saudi Arabia	

AMERICA

Argentina	Dominican Republic	Panama
Bolivia	Ecuador	Paraguay
Brazil	El Salvador	Peru
Canada	Guatemala	United States
Chile	Honduras	Uruguay
Colombia	Mexico	Venezuela
Costa Rica	Nicaragua	

OCEANIA

Australia	Algeria	South Africa
	Republic of Benin	Tanzania
	Egypt	Senegal
	Kenya	Sudan
	Madagascar	Tunisia

AFRICA

Thank you